BIOVICA INTERNATIONAL AB

Their core work

Biovica is a Swedish diagnostics SME built around a single proprietary product: the DiviTum assay, a blood-based test that measures thymidine kinase 1 (TK1) activity as a proxy for cell proliferation rate. Their core work is clinical validation — running prospective studies in European cancer centers to prove that DiviTum can predict and monitor patient response to cell-cycle targeting therapies, particularly CDK4/6 inhibitors used in breast cancer treatment. They operate at the intersection of liquid biopsy diagnostics and oncology pharmacodynamics, generating the clinical evidence needed to bring a biomarker assay to market. Both of their EU-funded projects were self-led, reflecting a company that moves its own product forward rather than serving as a research subcontractor.

What they specialise in

How they've shifted over time

Their first project (CVDTEU, 2014–2015) was a lean market-entry study — a €50,000 feasibility effort to validate DiviTum across European markets with no documented therapeutic specificity. The second project (BIOVALID, 2015–2021) was a full clinical program at thirteen times the budget, now anchored in a specific and commercially high-value context: monitoring CDK-inhibitor response in breast cancer patients. This shift reflects a deliberate narrowing from broad market validation to deep therapeutic positioning, timed precisely as CDK4/6 inhibitors (palbociclib, ribociclib) were becoming blockbuster drugs in oncology.

Biovica is moving toward becoming the standard pharmacodynamic monitoring tool for CDK-inhibitor therapies in breast cancer — a very defined commercial niche that requires clinical evidence partners, oncology centers, and pharma co-development deals rather than broad consortium work.

How they like to work

Biovica consistently leads projects as sole coordinator under the SME Instrument, which means they work independently rather than inside multi-partner consortia — both H2020 projects list zero unique consortium partners. This is characteristic of a product-focused company using EU grants to fund internal clinical development rather than to collaborate with research institutions. Anyone approaching them as a partner should expect to be a clinical study site, a pharma co-development partner, or a distribution channel — not a co-investigator in a shared research program.

Biovica has no recorded EU consortium partnerships — both projects were run as single-beneficiary SME Instrument grants. Their operational network almost certainly runs through clinical study sites and hospital oncology departments across Europe, but these relationships are not captured in CORDIS project data.

What sets them apart

Biovica occupies a narrow but commercially precise niche: they own the DiviTum assay, one of the few blood-based tests designed specifically to measure cell proliferation as a dynamic, on-treatment biomarker rather than a static tissue marker. Unlike academic groups working on CDK-inhibitor biomarkers, Biovica is a commercial entity with a CE-marked product seeking clinical adoption and pharma partnerships. For a consortium needing a diagnostics company with proprietary liquid biopsy technology validated in breast cancer clinical trials, there are very few direct equivalents in Sweden or the broader EU SME landscape.

Highlights from their portfolio

• BIOVALID
  Their flagship project — €682,506 and six years of clinical work — represents the full clinical validation of DiviTum in CDK-inhibitor breast cancer trials, directly supporting regulatory and commercial market entry.
• CVDTEU
  A rapid, low-cost (€50,000) market feasibility study that seeded the larger BIOVALID program, demonstrating Biovica's phased, evidence-building commercial strategy.